{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T19:56:58Z","timestamp":1794859018598,"version":"4.9.1"},"reference-count":28,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,8,14]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Twice-weekly oral ixazomib appears tolerable, with no severe neuropathy seen to date, in heavily pretreated multiple myeloma patients. These phase 1 data suggest clinical activity including 76% stable disease or better, with durable responses and sustained disease control.<\/jats:p>","DOI":"10.1182\/blood-2014-01-548826","type":"journal-article","created":{"date-parts":[[2014,6,12]],"date-time":"2014-06-12T09:05:43Z","timestamp":1402563943000},"page":"1038-1046","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":180,"title":["Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed\/refractory multiple myeloma patients"],"prefix":"10.1182","volume":"124","author":[{"given":"Paul G.","family":"Richardson","sequence":"first","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachid","family":"Baz","sequence":"additional","affiliation":[{"name":"H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wang","sequence":"additional","affiliation":[{"name":"The University of Texas MD. Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej J.","family":"Jakubowiak","sequence":"additional","affiliation":[{"name":"University of Michigan Comprehensive Cancer Center, Ann Arbor, MI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob P.","family":"Laubach","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Donald","family":"Harvey","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute, Emory University, Atlanta, GA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Talpaz","sequence":"additional","affiliation":[{"name":"University of Michigan Comprehensive Cancer Center, Ann Arbor, MI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Berg","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International Co., Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohui","family":"Liu","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International Co., Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Yu","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International Co., Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Gupta","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International Co., Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Di Bacco","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International Co., Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-Min","family":"Hui","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International Co., Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute, Emory University, Atlanta, GA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5","key":"2019111819481788400_B1","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1182\/blood-2012-04-403733","article-title":"Proteasome inhibitors in multiple myeloma: 10 years later.","volume":"120","author":"Moreau","year":"2012","journal-title":"Blood"},{"issue":"26","key":"2019111819481788400_B2","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma.","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"issue":"24","key":"2019111819481788400_B3","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111819481788400_B4","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1200\/JCO.2012.41.6180","article-title":"Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.","volume":"31","author":"San Miguel","year":"2013","journal-title":"J Clin Oncol"},{"key":"2019111819481788400_B5","unstructured":"Millennium: The Takeda Oncology Company. VELCADE\u00ae (bortezomib) for injection. Prescribing information. October 2012, Revision 15. http:\/\/www.velcade.com\/files\/PDFs\/VELCADE_PRESCRIBING_INFORMATION.pdf. Accessed November 1, 2013"},{"key":"2019111819481788400_B6","unstructured":"Janssen-Cilag International NV\n          VELCADE\u00ae (bortezomib) Summary of Product Characteristics. October 2012. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000539\/WC500048471.pdf. Accessed November 1, 2013"},{"issue":"6","key":"2019111819481788400_B7","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2012-10-459883","article-title":"Carfilzomib.","volume":"121","author":"Kortuem","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2019111819481788400_B8","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1586\/era.13.9","article-title":"Proteasome inhibitors in the treatment of multiple myeloma.","volume":"13","author":"McBride","year":"2013","journal-title":"Expert Rev Anticancer Ther"},{"issue":"5","key":"2019111819481788400_B9","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1158\/0008-5472.CAN-09-2766","article-title":"Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer.","volume":"70","author":"Kupperman","year":"2010","journal-title":"Cancer Res"},{"issue":"16","key":"2019111819481788400_B10","doi-asserted-by":"crossref","first-page":"5311","DOI":"10.1158\/1078-0432.CCR-11-0476","article-title":"In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.","volume":"17","author":"Chauhan","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"23","key":"2019111819481788400_B11","doi-asserted-by":"crossref","first-page":"7313","DOI":"10.1158\/1078-0432.CCR-11-0636","article-title":"Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies.","volume":"17","author":"Lee","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"19","key":"2019111819481788400_B12","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1182\/blood-2012-01-401794","article-title":"Investigational agent MLN9708\/2238 targets tumor-suppressor miR33b in MM cells.","volume":"120","author":"Tian","year":"2012","journal-title":"Blood"},{"key":"2019111819481788400_B13","article-title":"Weekly dosing of the investigational oral proteasome inhibitor ixazomib in relapsed\/refractory multiple myeloma: results from a phase 1 study [published online ahead of print June 5, 2014].","author":"Kumar","journal-title":"Blood"},{"issue":"14","key":"2019111819481788400_B14","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","article-title":"A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.","volume":"120","author":"Siegel","year":"2012","journal-title":"Blood"},{"issue":"24","key":"2019111819481788400_B15","doi-asserted-by":"crossref","first-page":"5661","DOI":"10.1182\/blood-2012-03-414359","article-title":"An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and\/or refractory multiple myeloma.","volume":"119","author":"Vij","year":"2012","journal-title":"Blood"},{"issue":"9","key":"2019111819481788400_B16","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma.","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"issue":"5","key":"2019111819481788400_B17","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","article-title":"Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation.","volume":"102","author":"Blad\u00e9","year":"1998","journal-title":"Br J Haematol"},{"issue":"21","key":"2019111819481788400_B18","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1182\/blood.V118.21.1433.1433","article-title":"Flat-dosing versus BSA-based dosing for MLN9708, an investigational proteasome inhibitor: population pharmacokinetic (PK) analysis of pooled data from 4 phase-1 studies.","volume":"118","author":"Gupta","year":"2011","journal-title":"Blood"},{"key":"2019111819481788400_B19","author":"Gupta"},{"issue":"21","key":"2019111819481788400_B20","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1182\/blood.V120.21.332.332","article-title":"A phase 1\/2 study of weekly MLN9708, an investigational oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma (MM).","volume":"120","author":"Kumar","year":"2012","journal-title":"Blood"},{"issue":"21","key":"2019111819481788400_B21","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1182\/blood.V120.21.731.731","article-title":"MLN9708, a novel, investigational oral proteasome inhibitor, in patients with relapsed or refractory light-chain amyloidosis (AL): results of a phase 1 study.","volume":"120","author":"Merlini","year":"2012","journal-title":"Blood"},{"issue":"2","key":"2019111819481788400_B22","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1365-2141.2008.07321.x","article-title":"Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma.","volume":"143","author":"Lonial","year":"2008","journal-title":"Br J Haematol"},{"issue":"12","key":"2019111819481788400_B23","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1182\/blood-2005-03-1173","article-title":"Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.","volume":"106","author":"Lonial","year":"2005","journal-title":"Blood"},{"issue":"s1","key":"2019111819481788400_B24","first-page":"601","article-title":"Hematologic safety profile of single-agent carfilzomib in patients with relapsed and\/or refractory multiple myeloma from four phase 2 studies.","volume":"97","author":"Nooka","year":"2012","journal-title":"Haematologica"},{"issue":"4","key":"2019111819481788400_B25","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/leu.2011.346","article-title":"Management of treatment-emergent peripheral neuropathy in multiple myeloma.","volume":"26","author":"Richardson","year":"2012","journal-title":"Leukemia"},{"issue":"19","key":"2019111819481788400_B26","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO.2005.04.7779","article-title":"Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.","volume":"24","author":"Richardson","year":"2006","journal-title":"J Clin Oncol"},{"issue":"s1","key":"2019111819481788400_B27","first-page":"473","article-title":"MLN9708, an investigational proteasome inhibitor, combined with lenalidomide and dexamethasone in previously untreated multiple myeloma patients: Evaluation of weekly and twice-weekly dosing regimens.","volume":"97","author":"Richardson","year":"2012","journal-title":"Haematologica"},{"issue":"s1","key":"2019111819481788400_B28","first-page":"118","article-title":"Oral MLN9708, an investigational proteasome inhibitor, in combination with melphalan and prednisone in patients with previously untreated multiple myeloma: A phase 1 study.","volume":"97","author":"San Miguel","year":"2012","journal-title":"Haematologica"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/124\/7\/1038\/1383094\/1038.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/124\/7\/1038\/1383094\/1038.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T01:01:44Z","timestamp":1574125304000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/124\/7\/1038\/33629\/Phase-1-study-of-twiceweekly-ixazomib-an-oral"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,14]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,8,14]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2014-01-548826","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,14]]}}}